而针对Optune此前开展的国际临床3期试验结果表明，相比于单独使用TMZ治疗，TTFields和TMZ联合使用治疗新发GBM，患者的五年总生存率（OS）由5%提升到了 ...

EF-14试验是十多年来，在不考虑患者特征的情况下用于证明新诊断的胶质母细胞瘤患者在统计上和临床上总生存期显着延长的第一个试验。NovoCure公司 ...

Optune是十多年来FDA核准的首个对新诊断GBM总生存期延长有统计学意义的治疗方法。Optune联合替莫唑胺治疗组患者的2年生存率比单用替莫唑胺组高50%。

目前，用于治疗胶质母细胞瘤（简称GBM）的 Optune，已经在美国、欧洲、日本等地区上市，且在全球其应用于其他多个实体肿瘤适应症的临床试验正在 ...

胶质母细胞瘤（gbm）作为最常见且具有侵袭性的成人脑肿瘤，患者复发率高达100% ，五年生存率低于5%，被认为是神经外科治疗中最棘手的难治性肿瘤 ...

在商业化表现上，目前TTF全球领先者Novocure公司的产品Optune®（中文名：爱普盾）已获得FDA批准的三种适应症：新发GBM、复发GBM和不可切除的恶性胸膜 ...

"He is literally the most inspirational person in my life and the most positive person," Jessica Smallwood told Newsweek.

Optune is now available as a treatment for newly diagnosed glioblastoma patients in France Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with ...

Novocure (NASDAQ: NVCR) today announced that Health Canada has approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma (GBM). GBM is the most common and one of the most ...

Optune is the first treatment for glioblastoma approved in Canada in over 12 years Novocure is actively working to secure reimbursement of Optune to make the therapy accessible for glioblastoma.